In the Claims:

Please amend the above-identified application as set forth below.

(Currently Amended) A method of inducing pancreatic hormone expression in the liver
of a mammal, wherein said pancreatic hormone is selected from the group consisting of
insulin, somatostatin, and glucagon, said method comprising administering to a mammal
an adenoviral particle comprising an adenovirus vector comprising a cytomegalovirus
(CMV) promoter operably linked to a nucleic acid encoding a pancreatic and duodenal
homobox 1 (PDX-1) polypeptide in an amount sufficient to induce said pancreatic
hormone expression in said liver in said mammal.

2. - 9. (Cancelled)

- (Previously Amended) The method of claim 1, wherein administering said vector increases hepatic insulin levels in said mammal.
- 11. (Previously Amended) The method of claim 1, wherein administering said vector increases serum insulin levels in said mammal.
- 12. (Previously Amended) The method of claim 1, wherein the mammal is a rodent or human.
- 13. (Previously Amended) The method of claim 1, wherein the mammal is further administered a transfection agent.
- 14. (Cancelled)
- 15. (Previously Amended) The method of claim 1, wherein the administering is by a route selected from the group consisting of intraperitoneal, subcutaneous, nasal, intravenous, oral and transdermal delivery.

16. - 28. (Cancelled)

- 29. (Currently Amended) A method of inducing a pancreatic islet gene expression profile in a liver cell of a subject, said method comprising administering to a subject an adenoviral particle comprising an adenovirus vector comprising a cytomegalovirus (CMV) promoter operably linked to a nucleic acid encoding a pancreatic and duodenal homobox 1 (PDX-1) polypeptide in an amount sufficient to induce said pancreatic islet gene expression in said liver cell in said subject.
- 30. (Original) The method of claim 29, wherein said pancreatic islet gene is insulin.
- 31. 32. (Cancelled)
- 33. (Currently Amended) A method of inducing insulin expression in the liver of a mammal, said method comprising administering to a mammal an <u>adenoviral particle comprising an</u> adenovirus vector comprising a cytomegalovirus (CMV) promoter operably linked to a nucleic acid encoding a pancreatic and duodenal homobox 1 (PDX-1) polypeptide in an amount sufficient to induce said insulin expression in said liver of said mammal.
- 34. (Currently Amended) A method of inducing glucagon expression in the liver of a mammal, said method comprising administering to a mammal an adenoviral particle comprising an adenovirus vector comprising a cytomegalovirus (CMV) promoter operably linked to a nucleic acid encoding a pancreatic and duodenal homobox 1 (PDX-1) polypeptide in an amount sufficient to induce said glucagon expression in said liver of said mammal.

- 35. (Currently Amended) A method of inducing somatostatin expression in the liver of a mammal, said method comprising administering to a mammal an adenoviral particle comprising an adenovirus vector comprising a cytomegalovirus (CMV) promoter operably linked to a nucleic acid encoding a pancreatic and duodenal homobox 1 (PDX-1) polypeptide in an amount sufficient to induce said somatostatin expression in said liver of said mammal.
- 36. (Currently Amended) A method of inducing prohormone convertase 1/3 (PC 1/3) expression in the liver of a mammal, said method comprising administering to a mammal an adenoviral particle comprising an adenovirus vector comprising a cytomegalovirus (CMV) promoter operably linked to a nucleic acid encoding a pancreatic and duodenal homobox 1 (PDX-1) polypeptide in an amount sufficient to induce said PC 1/3 expression in said liver of said mammal.
- 37. (Previously Added) A method of inducing pancreatic hormone expression in a liver cell, wherein said pancreatic hormone is selected from the group consisting of insulin, somatostatin, and glucagon, said method comprising contacting said cell with an adenovirus vector comprising a cytomegalovirus (CMV) promoter operably linked to a nucleic acid encoding a pancreatic and duodenal homobox 1 (PDX-1) polypeptide, thereby inducing said pancreatic hormone expression in said liver cell.
- 38. (Previously Added) A method of inducing insulin expression in a liver cell, said method comprising contacting said cell with an adenovirus vector comprising a cytomegalovirus (CMV) promoter operably linked to a nucleic acid encoding a pancreatic and duodenal homobox 1 (PDX-1) polypeptide, thereby inducing said insulin expression in said liver cell.

- 39. (Previously Added) A method of inducing somatostatin expression in a liver cell, said method comprising contacting said cell with an adenovirus vector comprising a cytomegalovirus (CMV) promoter operably linked to a nucleic acid encoding a pancreatic and duodenal homobox 1 (PDX-1) polypeptide, thereby inducing said somatostatin expression in said liver cell.
- 40. (Previously Added) A method of inducing glucagon expression in a liver cell, said method comprising contacting said cell with an adenovirus vector comprising a cytomegalovirus (CMV) promoter operably linked to a nucleic acid encoding a pancreatic and duodenal homobox 1 (PDX-1) polypeptide, thereby inducing said glucagon expression in said liver cell.
- 41. (Previously Added) A method of inducing prohormone convertase 1/3 (PC 1/3) expression in a liver cell, said method comprising contacting said cell with an adenovirus vector comprising a cytomegalovirus (CMV) promoter operably linked to a nucleic acid encoding a pancreatic and duodenal homobox 1 (PDX-1) polypeptide, thereby inducing said PC 1/3 expression in said liver cell.
- 42. (Previously Added) A composition comprising an adenovirus vector comprising a cytomegalovirus (CMV) promoter operably linked to a nucleic acid encoding a pancreatic and duodenal homobox 1 (PDX-1) polypeptide, and a carrier.